Activating EGFR mutations are the known drivers of lung cancer that accounts for approximately 10 to 15% of non-small cell lung cancer (NSCLC) diagnoses [2–5] and assessment of EGFR mutations is now routinely performed as standard of care. Here, EGFR is linked to non-small cell lung carcinoma.